Category Archives: Global News Feed

PALO ALTO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of its management team, along with Ravi Savarirayan, M.D., Ph.D., of Murdoch Children’s Research Institute in Melbourne, Australia, and the global lead investigator for PROPEL 2, will host a call on June 4, 2024, at 8:00 am ET to share results from Month 12 and Month 18 from Cohort 5 of PROPEL 2, a Phase 2 trial of the investigational oral therapy infigratinib in children with achondroplasia.

The rest is here:
BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024

-  40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated with TransCon IL-2 ?/? in combination with TransCon TLR7/8 Agonist exhibited confirmed clinical responses with no new safety signals

Continue reading here:
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) of FG-3165, a galectin-9 (Gal9) targeted monoclonal antibody under development for treatment of solid tumors characterized by high Gal9 levels of expression.

Read the rest here:
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of...

- Participants from the completed Phase 2 hypothalamic obesity trial reported positive changes in sleep, energy levels during setmelanotide therapy in qualitative interviews -

See the original post here:
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024

SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical?stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10 at 4:00 pm ET.

Continue reading here:
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

SAN JOSE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Truist Securities MedTech Conference in Boston, Massachusetts. Management is scheduled to present on Tuesday, June 18 at 1:20 p.m. Eastern Time.

Read more:
PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024

73 percent reduction in risk of disease progression or death seen with cilta-cel in the CARTITUDE-4 study in a subset of patients who had early relapse after initial multiple myeloma therapy1

Continue reading here:
CARVYKTI®? (ciltacabtagene autoleucel; cilta-cel) significantly improved progression-free survival and deepened responses versus two standard...

CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on May 28, 2024, the Compensation Committee of Spero’s Board of Directors approved the grant of 116,667 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The RSUs are being granted as an inducement material to the new employee becoming an employee of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).

Go here to see the original:
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics (ACMG), published a new study validating RiskScore®, Myriad’s breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test. RiskScore combines a polygenic risk score (PRS) validated for all ancestries with the Tyrer-Cuzick model, a widely used breast cancer risk assessment calculator.

The rest is here:
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool

SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate FibroGen’s immuno-oncology assets, FG-3165 and FG-3175, in combination with Regeneron’s anti-PD-1 therapy, LIBTAYO® (cemiplimab), in patients with solid tumors.

View post:
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165...